Book a Meeting

Non-Fucosylated Anti-Human Glycosphingolipid globotriaosylceramide (3E2) Therapeutic Antibody (CAT#: BioBet-907ZP) Datasheet

Target
Glycosphingolipid globotriaosylceramide
Isotype
IgG
Description
ADCC-Enhanced anti-Glycosphingolipid globotriaosylceramide (3E2) is a non-fucosylated therapeutic biobetter antibody engineered by Creative Biolabs' Afuco™ technology platform.
Indication
Solid Tumors
Classification
Therapeutic antibody; biobetter

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced Glycosphingolipid globotriaosylceramide antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
Gb3
Full Name
gastrin
Background
Globotriaosylceramide is a ganglioside. It is also known as CD77, Gb3, and ceramide trihexoside. It is one of the few clusters of differentiation that is not a protein. It is formed by the alpha linkage of galactose to lactosylceramide catalyzed by A4GALT. It is metabolized by alpha-galactosidase, which hydrolyzes the terminal alpha linkage. Defects in the enzyme alpha-galactosidase lead to the build up of globotriaosylceramide, causing Fabry's disease. Globotriaosylceramide is also one of the targets of Shiga toxin, which is responsible for pathogenicity of enterohemorrhagic Escherichia coli (EHEC).
Alternative Names
Gb3; Glycosphingolipid globotriaosylceramide; CD77
Cellular Localization
Golgi apparatus
Involvement in Disease
Diseases associated with A4GALT include Blood Group, P1pk System and Caffey Disease.
Related Pathways
Its related pathways are Glycosphingolipid biosynthesis - lacto and neolacto series and Metabolism.
Function
Catalyzes the conversion of galactose from udp--d -galactose to lactose ceramide/-d -galactosyl-(1->4)--d -glucosyl-(1<->1)-ceramide (d18: 1(4E)) to generate globotriaosylide /globoside Gb3Cer (d18:1(4E)). It can also convert galactose into galactose ceramide/-d-gal -(1<->1')-cer. Globoside Gb3Cer is a glycophospholipid of the globo series. It is one of the main types of the neutral root structure of glycophospholipids and constitutes an important part of mammalian cell membranes (possibly). The globulin-Gb3Cer in blood and tissue cell membrane is the antigen Pk of blood tissue group p (microbial infection). Globulin is one of the cell ligands of bacterial vero toxin.
Post-translational modifications
1.Glycosylation at Asn121 and Asn203 2.Modification sites at PhosphoSitePlus
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG
Antibody Clone
3E2
Host
Humanized
Species Reactivity
Human
Description
The anti-Gb3 antibody having specific CDR sequences are used for the treatment of diseases associated with angiogenesis, such as solid tumors.
Indication
Solid Tumors

Solid Tumors

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK

Germany

ISO 9001 Certified - Creative Biolabs Quality Management System.